Amplia Therapeutics is pleased to announce that a poster, detailing a series of preclinical studies in pancreatic cancer models, was presented overnight at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Pancreatic Cancer, currently being held in Boston, USA.
The poster shows data demonstrating that in disease-bearing mice narmafotinib (AMP945) significantly reduces pancreatic cancer associated fibrosis through inhibition of FAK activity. Further, in a number of in vivo pancreatic cancer models, narmafotinib can be utilised to improve chemotherapy response.
Amplia’s CEO Dr Chris Burns commented:
“We are delighted that this extensive body of research from The Garvan Institute on our best-in-class FAK inhibitor narmafotinib is being presented at such a prestigious conference. The Garvan team have done an outstanding job and this poster represents the first public disclosure of the breadth of that work demonstrating the impressive activity of the drug in these preclinical studies.”
Click here to view the presentation.